These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inflammatory myofibroblastic tumor of the uterus - case report. Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556 [TBL] [Abstract][Full Text] [Related]
3. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z Front Oncol; 2023; 13():1147974. PubMed ID: 37035208 [TBL] [Abstract][Full Text] [Related]
4. TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. Lee J; Singh A; Ali SM; Lin DI; Klempner SJ Acta Med Acad; 2019 Apr; 48(1):116-120. PubMed ID: 31264439 [TBL] [Abstract][Full Text] [Related]
5. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150 [TBL] [Abstract][Full Text] [Related]
6. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS Front Oncol; 2022; 12():761558. PubMed ID: 35237506 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors. Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888 [TBL] [Abstract][Full Text] [Related]
8. Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib. Sunga CGG; Higgins MS; Ricciotti RW; Liu YJ; Cranmer LD Cancer Rep (Hoboken); 2023 Mar; 6(3):e1792. PubMed ID: 36754839 [TBL] [Abstract][Full Text] [Related]
9. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review. Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188 [TBL] [Abstract][Full Text] [Related]
10. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823 [TBL] [Abstract][Full Text] [Related]
11. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases. Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797 [TBL] [Abstract][Full Text] [Related]
12. Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib. Fujiki T; Sakai Y; Ikawa Y; Takenaka M; Noguchi K; Kuroda R; Abe T; Nomura K; Sakai S; Wada T Pediatr Blood Cancer; 2023 Apr; 70(4):e30172. PubMed ID: 36635892 [TBL] [Abstract][Full Text] [Related]
13. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms. Bowman CJ; Medeiros F; Fadare O; Sangoi AR; Horvai AE; Devine WP; McCluggage WG; Rabban JT Int J Gynecol Pathol; 2023 Jan; 42(1):1-10. PubMed ID: 35180768 [TBL] [Abstract][Full Text] [Related]
14. Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib. Testa S; Million L; Longacre T; Bui N Case Rep Oncol; 2021; 14(2):812-819. PubMed ID: 34248545 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Rabban JT; Zaloudek CJ; Shekitka KM; Tavassoli FA Am J Surg Pathol; 2005 Oct; 29(10):1348-55. PubMed ID: 16160478 [TBL] [Abstract][Full Text] [Related]
16. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib. Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097 [TBL] [Abstract][Full Text] [Related]
17. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. Parker BM; Parker JV; Lymperopoulos A; Konda V J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295 [TBL] [Abstract][Full Text] [Related]
18. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor. Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016 [TBL] [Abstract][Full Text] [Related]
19. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720 [TBL] [Abstract][Full Text] [Related]
20. Histopathologic and Molecular Characterization of Uterine Leiomyoma-like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of Uterine Leiomyoma. Kuisma H; Jokinen V; Pasanen A; Heikinheimo O; Karhu A; Välimäki N; Aaltonen L; Bützow R Am J Surg Pathol; 2022 Aug; 46(8):1126-1136. PubMed ID: 35426837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]